Challenges in the development of drugs and biopharmaceuticals in Brazil
The COVID-19 pandemic has created strong pressure on national and international research systems for the production of vaccines and drugs. This webinar aims to discuss the challenges of the various sectors involved in the complex Brazilian research ecosystem, which includes universities, research centers, pharmaceutical and R&D companies, startups, companies specializing in clinical trials and hospitals. Uncertainties in the initial stages of product research and development, risks in the stages of pre-clinical testing, costs of clinical trials and those linked to the licensing process by the national regulatory body will be discussed. Local or imported production of active pharmaceutical ingredients, availability of inputs for research and development, the installed capacity of the Brazilian industry, as well as examples of financing innovation in the pharmaceutical industry will also be addressed.
Luiz Eugênio Mello – scientific director, FAPESP
Catarina Porto – Federal University of São Paulo (Unifesp) and FAPESP
Glaucius Oliva – São Carlos Physics Institute, University of São Paulo and Center for Innovation in Biodiversity and Drug Discovery (CIBFar / CEPID-FAPESP)
Carlos Augusto Grabois Gadelha – Oswaldo Cruz Foundation (Fiocruz)
Luiz Vicente Rizzo – Albert Einstein Education and Research Israeli Institute
Glauco Antonio Truzzi Arbix – Institute of Advanced Studies, University of São Paulo (IEA-USP)
There will be no certificate/declaration of presence for events broadcast on YouTube.
You can participate in a Q & A panel. Please, send your comments and questions (in English or Portuguese) to email@example.com.